Europe approves first retinal microchip implant to treat age-related vision loss

European regulators have granted CE mark approval for the PRIMA subretinal eye implant developed by Science Corporation, marking the first approval in Europe for a microchip designed to treat severe vision loss caused by dry age-related macular degeneration. The condition affects millions of people worldwide and leads to the deterioration of central vision.

The miniature microchip is implanted beneath the retina, where it converts light into electrical signals to stimulate surviving nerve cells. Industry observers view the regulatory clearance as a major milestone in ophthalmology, providing a new option for a condition that previously had limited treatment possibilities. The technology will now undergo further deployment across European medical centers.

Sources: FAZ.